Postmenopausal women with early-stage BC/low recurrence score could skip adjuvant chemo

(American Association for Cancer Research) After a median follow-up of 5.1 years, among women with lymph node-positive early-stage breast cancer and a recurrence score of 25 or lower who received adjuvant endocrine therapy with or without chemotherapy, postmenopausal patients had no added benefit from chemotherapy, while premenopausal patients who received chemotherapy had improved invasive disease-free survival (IDFS) and an early indication of improved overall survival (OS), according to data from the SWOG S1007 RxPONDER clinical trial.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news